Respiratory RTM for Pulmonology: COPD and Asthma

Why COPD and Asthma Are Ideal RTM Candidates

COPD and asthma share a characteristic that makes them especially well-suited for remote therapeutic monitoring: exacerbations do not emerge suddenly. They build over days, with measurable changes in symptoms (dyspnea, cough, sputum production, wheeze), functional capacity (activity limitation, nocturnal symptoms), and, in asthma, measurable changes in peak expiratory flow rate. This trajectory means there is a detection window — typically 48-96 hours before a clinically significant exacerbation — during which intervention can prevent ED visits, hospitalizations, and disease progression.

The burden of COPD exacerbations is substantial. A moderate COPD exacerbation requiring oral steroid treatment costs an average of $1,800 in ambulatory care. A severe exacerbation requiring hospitalization averages $39,200 per admission. Patients with GOLD Stage III-IV COPD average 2-3 exacerbations per year, with each exacerbation associated with accelerated lung function decline and increased mortality risk.

For asthma, the RTM opportunity is slightly different: asthma is characterized by variability (good control periods alternating with poorly controlled periods), and inhaler adherence is the single most modifiable risk factor for exacerbation prevention. Studies show that 50-70% of asthma patients are non-adherent to controller inhaler therapy — not taking their inhaled corticosteroid (ICS) daily as prescribed. RTM that tracks rescue inhaler (SABA) use and controller inhaler adherence provides actionable adherence data that drives clinical intervention before the pattern of non-adherence produces an exacerbation.

Both conditions meet Medicare RTM eligibility criteria — they are chronic conditions where monitoring of therapeutic adherence (medication use) and non-physiologic therapeutic response (dyspnea, activity tolerance, symptom frequency) generates data that can directly inform clinical management. This is the clinical and billing foundation for pulmonology RTM programs.

What to Monitor: COPD Data Elements and Alert Thresholds

A clinically useful COPD RTM program monitors multiple data streams simultaneously — dyspnea severity, activity tolerance, sputum character, rescue inhaler use, and peak flow if appropriate. Monitoring a single symptom misses the composite picture that characterizes the early exacerbation trajectory.

COPD RTM monitoring parameters:

Dyspnea score (Modified Borg Scale or mMRC): Patient rates dyspnea on a 0-10 scale daily. Alert threshold: two consecutive days with dyspnea score increasing by ≥2 points above patient's personal baseline, or single reading ≥7/10 in a patient with baseline ≤4.

Rescue inhaler (SABA) use: Patient logs daily number of puffs of albuterol or levalbuterol. Alert threshold: >4 puffs/day on two consecutive days (above GOLD guideline threshold for inadequate control) or >8 puffs in any 24-hour period.

Sputum character: Daily symptom questionnaire asks: Is your sputum more than usual? Has the color changed (from white to yellow or green)? Alert threshold: positive response to both questions on two consecutive days (purulent sputum + increased volume = bacterial exacerbation signal per Winnipeg criteria).

Activity tolerance: Patient rates ability to perform activities compared to usual (1-5 scale: 1 = same as usual, 5 = severely limited). Alert threshold: score ≥4 on two consecutive days.

Peak flow (where applicable): For COPD patients who have peak flow meters and adequate technique, a peak flow reading <70% of personal best on two consecutive mornings is a significant exacerbation signal.

Composite exacerbation risk score: the most sophisticated RTM platforms compute a composite daily score from multiple data streams, generating a single alert that combines symptom burden into a green/yellow/red risk indicator. Yellow triggers an MA outreach call; red triggers same-day provider review and patient contact. This composite approach reduces alert fatigue compared to individual-threshold alerting systems.

Asthma RTM: Inhaler Adherence and Control Monitoring

Asthma RTM has a different design emphasis than COPD RTM. Where COPD monitoring focuses on exacerbation early warning, asthma monitoring focuses on control assessment and adherence intervention — because most poorly controlled asthma is attributable to medication non-adherence or inadequate controller therapy rather than disease progression.

Validated asthma control tools adapted for RTM:

Asthma Control Test (ACT): A 5-question validated instrument that assesses activity limitation, awakening due to asthma, rescue inhaler frequency, overall control rating, and daytime symptom frequency. Administered weekly via RTM platform. Score ≤19 = not well controlled; score ≤15 = very poorly controlled. Alert triggers: ACT score ≤19 for 2 consecutive weeks, or ACT ≤15 on any single assessment.

Rescue inhaler use tracking: Same threshold as COPD — >2 days per week of rescue inhaler use is the NAEPP/GINA definition of uncontrolled asthma. Alert threshold: >2 days in the past 7-day period with SABA use documented.

Controller adherence tracking: Patient logs whether they took their ICS or ICS/LABA inhaler each morning and evening. Alert threshold: <70% adherence over any 7-day period (missed ≥4 of 14 scheduled doses). For adherence interventions, the RTM platform should automatically trigger an MA educational call that addresses barriers — side effect concerns, cost (LABAs can exceed $200-$400/month without assistance), technique errors, or forgetfulness.

Nighttime symptom tracking: Patient answers daily: "Did asthma wake you up last night?" Alert threshold: 2+ nights per week with nighttime awakening — a marker of Step 3 or higher asthma severity per NAEPP guidelines, triggering controller step-up evaluation.

Spirometry correlation: when an RTM platform shows deteriorating ACT scores over 4-6 weeks, the clinical response should include an office spirometry measurement to confirm objective function change. RTM triggers the clinical evaluation; the clinical evaluation guides medication escalation or additional diagnostic workup.

RTM Code Selection and Billing for Pulmonology

Pulmonology RTM billing uses the same CPT 98975-98981 code set as other RTM specialties, but the specific codes appropriate for respiratory monitoring require careful selection based on what type of data is being monitored.

CPT 98975 — Initial device supply and patient education. Billed once per episode of care when the patient is onboarded to the RTM platform. ~$19 reimbursement.

CPT 98977 — Remote therapeutic monitoring of musculoskeletal system, 16+ days of data. Despite the "musculoskeletal" label in CMS coding language, 98977 covers non-physiologic data monitoring including functional status, pain, and medication adherence — which encompasses COPD and asthma symptom monitoring and inhaler adherence tracking. Confirm with your compliance team and MAC that 98977 is appropriate for your specific monitoring program. ~$48/month.

Important distinction: SpO2 (oxygen saturation) monitoring is a physiologic measure and is not billable under RTM codes — it falls under remote patient monitoring (RPM) codes 99453-99458. Practices that monitor SpO2 alongside symptom data should bill 99454 (device supply/transmission, RPM) and 99457 (RPM management) for the SpO2 component, and 98977 for the symptom/adherence component. Consult your compliance team on billing both code families for the same patient in the same month.

CPT 98980 — Treatment management, first 20 minutes of physician or QHP time reviewing RTM data and making clinical decisions. ~$50/month. This is the most critical billing code — it represents the physician's clinical work of reviewing symptom trends, responding to alerts, and making treatment decisions based on the data.

CPT 98981 — Additional 20 minutes of treatment management. ~$41/month. Applicable when a patient's complex exacerbation trajectory or medication management requires extended provider review time in the month.

Billing requirements recap: 16+ days of patient data transmission (for 98977); at least 20 minutes of documented QHP or physician review and management time per month (for 98980); physician order preceding enrollment; consent documented; device or app supplied to patient. The 16-day threshold is the most common compliance failure — track transmission days per patient monthly and reach out to non-transmitting patients before the month ends.

Revenue Math: COPD and Asthma RTM for a Pulmonology Practice

Building the revenue model for a pulmonology practice with 100 patients enrolled in a COPD/asthma RTM program (mix: 65 COPD, 35 asthma), using 2025 Medicare national non-facility rates:

Monthly RTM subtotal: $11,106 / Annual: $133,272

For practices also enrolling eligible patients in CCM (patients with COPD + one or more other chronic conditions = most COPD patients): - CPT 99490 (CCM, 20+ min clinical staff time): $62.00 × 70 dual-eligible patients = $4,340/month - CPT 99439 (add-on, 40% of dual patients reaching 40+ min): $47.00 × 28 = $1,316/month

CCM additional monthly: $5,656 / Annual: $67,872

Combined RTM + CCM annual gross revenue: $201,144 for 100 RTM patients + 70 CCM dual-enrolled.

Program costs: RTM platform ($10-13/patient/month × 100 = $12,000-$15,600/year) + respiratory nurse coordinator (0.4 FTE at $70,000 salary = $28,000/year). Net contribution: $157,544-$161,144/year.

Non-financial value: a COPD patient whose exacerbation is detected via RTM and treated with a prednisone burst + antibiotic outpatient ($85 medication cost) instead of an ER visit + hospitalization ($39,200 average) represents enormous value to the payer and to the patient. Practices in value-based arrangements with shared savings components should quantify this prevention value explicitly in their payer negotiations.

Exacerbation Early Detection: Clinical Response Protocols

An RTM alert that does not produce a clinical response is worse than no RTM at all — it documents that the practice received a warning signal and did not act. Every COPD and asthma RTM alert threshold must have a defined clinical response protocol specifying who responds, how quickly, and what actions are taken.

COPD exacerbation response protocol (suggested framework):

Action plans — printed and digital — should be distributed to all RTM-enrolled COPD patients at enrollment. The action plan specifies exactly what symptoms trigger self-initiation of the prednisone/antibiotic course (standing prescription) versus calling the office versus going to the ED. Patients with a clear written action plan have 30-40% lower ED utilization for COPD exacerbations than those relying solely on "call if you feel worse."

Inhaler Adherence Intervention: From Data to Behavior Change

Detecting inhaler non-adherence through RTM is clinically valuable only if the practice has the infrastructure to translate that data into behavior change. An RTM program that flags non-adherence weekly without a systematic intervention is generating data without impact.

Non-adherence intervention cascade:

Forgetfulness intervention: Link inhaler use to an existing daily habit (morning coffee, tooth brushing). Set up phone app reminders if patient is smartphone-using. Consider once-daily dosing ICS formulations (budesonide 360 mcg once daily, fluticasone furoate) if currently on twice-daily dosing.

Side effect intervention: For oral candidiasis — rinse mouth and gargle after each ICS use; spacer device use reduces oropharyngeal deposition. For voice hoarseness — spacer device. If side effects persist, discuss alternative ICS molecule with lower oropharyngeal deposition (ciclesonide is a prodrug with minimal oropharyngeal activation).

Cost intervention: Screen for patient assistance programs (AstraZeneca, GSK, Sanofi all have PAPs for their respiratory inhalers). Generic budesonide (Pulmicort generic ~$50/month) as an alternative to branded ICS ($300-$450/month). If patient is Medicare with Low Income Subsidy, cost-sharing for inhalers may be minimal — verify.

Technique intervention: For patients with difficulty using MDI technique, recommend a spacer device (holding chamber) or switch to a DPI formulation. MA-led inhaler technique education session (15 minutes) with teach-back confirmation improves correct technique from ~30% in untrained patients to >85%.

Persistent non-adherence (>4 weeks below 70%): Provider discussion during scheduled visit. Explore ambivalence about medication necessity. Motivational interviewing techniques — "What concerns you about using the inhaler every day?" — reveal beliefs that brief educational interventions cannot address.

Building and Scaling the Pulmonology RTM Program

A pulmonology RTM program that starts with 20-30 pilot patients and scales to 100+ requires deliberate infrastructure development at each growth stage. The operational bottleneck shifts as the program scales: at 30 patients, the challenge is enrollment and onboarding; at 80+ patients, the challenge is alert management and billing reconciliation.

Vendor selection considerations for respiratory RTM: ensure the platform supports: (a) daily symptom questionnaire delivery via SMS or app, (b) custom alert threshold setting by patient (COPD patients have different baselines), (c) composite alert logic, (d) integration with EHR for data write-back, and (e) monthly transmission compliance reports that can be exported for billing documentation. Do not select a platform that requires manual data extraction for billing documentation — this becomes the limiting factor at scale.